Covid-19 roundup: Synairgen turns to post-hoc analyses after failed drug trial; EU terminates Valneva vaccine contract
After halting enrollment in an NIH-led Phase II/III study, and failing an earlier Phase III trial, UK-based Synairgen’s Covid-19 drug did show some promise in some select subgroups, the company said in its presentation of a post-hoc analysis on Monday at a conference in San Francisco.
Post-hoc analyses of the Phase III SPRINTER trial, which failed to hit its primary endpoints, showed an “encouraging signal in reduction in the relative risk (RRR) of progression to severe disease or death within 35 days (25.7% reduction in the Intention-to-Treat population and 36.3% reduction in the Per Protocol population).”
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters